BJT 778
Alternative Names: BJT-778Latest Information Update: 12 Aug 2024
At a glance
- Originator Novartis
- Developer Bluejay Therapeutics
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Hepatitis B surface antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Hepatitis B; Hepatitis D
Most Recent Events
- 05 Jun 2024 Pharmacodynamics data from a preclinical study in hepatitis B virus infections presented at the European Association for the Study of the Liver Congress 2024 (EASL -2024)
- 05 Jun 2024 Pharmacodynamics data from a trial in hepatitis B virus and hepatitis D virus infections presented at the European Association for the Study of the Liver Congress 2024 (EASL -2024)
- 05 Jun 2024 Updated pharmacokinetics, efficacy and adverse events data from a phase I/IIa trial in Hepatitis B and Hepatitis D presented at the European Association for the Study of the Liver Congress 2024 (EASL-2024)